Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195808 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL4591060 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL5923297 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL3204213 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL3204221 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL3204207 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2MGLLKMT2AMEN1LMNA | |
| SCHEMBL4590583 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1LMNATSHR | |
| SCHEMBL3201863 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1LMNATSHR | |
| SCHEMBL3201872 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1LMNATSHR | |
| SCHEMBL3194275 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | SMN1; SMN2 3782/4885MGLL 4489/4885KMT2A 1756/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | SMN1; SMN2 3782/4885MGLL 4489/4885KMT2A 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.